logo
Private NYC special ed school owes $800K in legal fees over sex harass, health violations: suit

Private NYC special ed school owes $800K in legal fees over sex harass, health violations: suit

Yahoo09-05-2025
A private special education school on the Upper East Side is accused of skipping out on $800,000 in legal bills to defend against sexual harassment claims and health violations, a new lawsuit claims.
But its founder blames the city's Department of Education for the debt, claiming that any lapse in payments is because of $6 million in funding that the Big Apple owes them.
The International Institute for the Brain, or iBRAIN, a specialty school for children with brain injuries and disorders, hired the elite law firm Pryor Cashman to solve a slew of legal headaches with the city, plus state and federal courts, back in 2023.
While the school has paid the firm roughly $81,000, it still owes a whopping $815,000, the suit claims.
'Despite Pryor Cashman's repeated good faith attempts to obtain payment from iBrain, iBrain has failed and refused to make payment,' reads the lawsuit, which was filed Wednesday in Manhattan Supreme Court.
The firm did not respond to a message seeking comment.
Pryor Cashman's legal work for iBrain took place during 2023 and ranged from advice on what to do about a former worker 'publicly disparaging' the school to helping 'resolve' unspecified health code violations.
iBrain was also represented by Pryor Cashman in a salacious civil lawsuit in state court in 2023, where a former employee claimed that the school was 'extremely filthy and unsanitary' — with dead rats visibly rotting and roaches crawling on students.
iBrain also sued the same 'disgruntled' worker in federal court for libel and 'malicious' copyright infringement, claiming she 'used and exploited copyrighted photographs of iBrain's disabled students as poster-children and pawns for her social media campaign of defamation.'
Both suits settled out of court, according to records and Pryor Cashman's lawsuit.
And when the firm sent iBrain its invoices, the school happily received them and partially paid up, but has been mum since.
iBrain never 'disputed the Invoices at any time,' the suit claims, adding that the firm has demanded the school pay up.
'iBrain has not responded to these demands.'
School founder Patrick Donohue told The Post that while he couldn't comment yet on the suit, he blamed the city's DOE for 'continued and purposeful delays.'
iBrain's students are all 'non-verbal and wheelchair-dependent, many of whom require nursing due to their complex medical conditions,' he said.
'The NYC DOE has a long history of withholding funds for special education students, and they are currently withholding over $6 million in tuition and related service funds for our students for just this school year,' Donohue said.
DOE officials did not immediately respond to a request for comment on the claim.
'We intend to fulfill any and all of our obligations as soon as the NYC DOE fulfills their legal and financial obligations to the families of iBRAIN,' Donohue said.
The single father — once a finance director for former Gov. George Pataki's winning campaign — founded the school after his newborn daughter suffered brain damage when her baby-nurse brutally attacked her.
According to court papers, iBrain charges 'only a $100 refundable deposit for enrollment,' with parents obtaining funding from the Individuals with Disabilities Education Act, in addition to public and private funding.
The school now has locations on the Upper East Side, Brooklyn and Washington, DC.
On Monday, the school held its inaugural iBrain Gala at the Central Park Boathouse — intentionally contrasting with the Met Gala — where their students made their way down a red carpet, some with the aid of futuristic exoskeleton devices.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Yahoo

time23 minutes ago

  • Yahoo

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

The Open Group Launches The Open Group Open Digital Transformation™ Forum
The Open Group Launches The Open Group Open Digital Transformation™ Forum

Yahoo

time23 minutes ago

  • Yahoo

The Open Group Launches The Open Group Open Digital Transformation™ Forum

Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Yahoo

time23 minutes ago

  • Yahoo

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store